PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.26
Both firms show negative OCF/share. Martin Whitman would suspect an industry-wide challenge or high growth burn rates.
-0.26
Both firms show negative FCF/share. Martin Whitman might see an industry-wide capital intensity challenge.
-1.22%
Negative ratio while CRVO is 0.00%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.
0.87
Ratio above 1.5x CRVO's 0.24. David Dodd would see if the business collects cash far more effectively.
-2398.28%
Negative ratio while CRVO is 0.00%. Joel Greenblatt would see if the company’s revenues or cash flows are fundamentally flawed.